The Worldwide Lysosomal Disease Treatment Industry is Expected to Reach $11 Billion by 2028

News provided by

Jan 13, 2023, 07:45 ET

DUBLIN, Jan. 13, 2023 /PRNewswire/ -- The "Global Lysosomal Disease Treatment Market Size, Share & Industry Trends Analysis Report By Disease Type (Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe's Syndrome), By Type of Therapy By End User, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

The Global Lysosomal Disease Treatment Market size is expected to reach $11 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Lysosomal diseases (LSDs) are a complex group of metabolic disorders that are often inherited in an autosomal recessive manner. There are currently 45 known diseases. They are caused by malfunctions in various lysosomal processes, most often by abnormalities in genes that produce catabolic enzymes responsible for the breakdown of macromolecules.

As the faulty enzyme accumulates substrate, cell malfunction and clinical symptoms escalate. Other types of lysosomal dysfunction that can lead to lysosomal storage include defects in post-translational processing of lysosomal enzymes, errors in enzyme trafficking or targeting, and dysfunction of non-enzymatic transmembrane and solubilize.

Lysosomal hydrolase mutations, which are implicated in the breakdown of cellular macromolecules, are the primary cause of LSDs, accounting for more than two-thirds of cases. As a result, there are many different types of lipids, glycogen, mucopolysaccharides, and glycoproteins among the storage products in LSDs that are biochemical in origin. The LSDs are all inherited as autosomal recessive characteristics, except the X-linked Fabry, Danon, and Hunter diseases.

The LSDs can affect the majority of organs, either alone or as part of a multisystem illness, and are clinically very heterogeneous. Even though lysosomal enzymes are housekeeping genes and expressed in the majority of cells, the tissues on which they act are distributed much less uniformly, and this determines which tissues in any individual are affected.

COVID-19 Impact Analysis

The COVID-19 public health crisis has affected almost every industry. The COVID-19 outbreak has caused a significant decrease in demand for the lysosomal disease treatment size of the market across several sectors, especially the health and pharmaceutical sector, as coronavirus crises sweep the globe and force healthcare providers to devote a large percentage of their funds to fighting COVID-19.

The risk of infection was the primary factor contributing to the delays in treatment that patients with lysosomal storage disorder encountered in hospitals. The COVID-19 outbreak harms the market's value in 2022 and beyond because it will delay the development of the worldwide market for lysosomal disease treatments.

Market Growth Factors

Incidence of Lysosomal Disorders Are Rising

The primary driving forces in the enzyme replacement therapy market are the expanding research and development for lysosomal disease diagnosis and drug development for treatment. The increasing incidence of lysosomal disease will be a key factor contributing to the acceleration of the market's growth rate.

According to a report published by the National Center for Biotechnology Information, the prevalence of Fabry disease in communities of white, male individuals ranged from 1:17,000 to 1:117,000 in January 2020. Atypical presentations were associated with around 1:6000-1:40,000 females and 1:1000-1:3000 males, whereas 1:22,000-1:40,000 males had the classic Fabry disease mutations.

Financial Incentives for Developing Orphan Drugs to Recoup R&D Expenses

The increases in healthcare spending, which helps to improve its infrastructure, is a crucial element affecting the market's growth rate for therapies for lysosomal diseases. The market dynamics will be further impacted by various government organizations' efforts to strengthen the healthcare infrastructure by boosting funding. Additionally, the market for lysosomal disease therapies will grow as a result of the rising acceptance rate of early diagnosis and the increasing number of government programs to raise awareness. Along with this, expanding government benevolent programs and an increase in disposable money is expected to accelerate market expansion.

Marketing Restraining Factor:

The Treatment of Stem Cells Is Fraught with Issues

Many of the issues that can arise soon after the transplant are caused by the bone marrow being destroyed just before it by drugs or radiation. Some may be unintended consequences of the conditioning procedures themselves. The patient can get support from the transplant team to manage side effects. Most can be addressed to make the patient feel better, and some can be prevented. This is not a comprehensive list, so please inform the physician or the transplant team of any issues or adjustments that experience.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Lysosomal Disease Treatment Market by Disease Type
3.1 Global Gaucher's Diseases Market by Region
3.2 Global Fabry Diseases Market by Region
3.3 Global Mucopolysaccharidosis Market by Region
3.4 Global Pompe's Syndrome Market by Region
3.5 Global Others Market by Region

Chapter 4. Global Lysosomal Disease Treatment Market by Type of Therapy
4.1 Global Enzyme Replacement Therapy Market by Region
4.2 Global Substrate Reduction Therapy Market by Region
4.3 Global Stem Cell Therapy Market by Region
4.4 Global Others Market by Region

Chapter 5. Global Lysosomal Disease Treatment Market by End User
5.1 Global Hospitals Market by Region
5.2 Global Clinics Market by Region
5.3 Global Others Market by Region

Chapter 6. Global Lysosomal Disease Treatment Market by Region

Chapter 7. Company Profiles
7.1 Merck & Co., Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Johnson & Johnson (Janssen Global Services, LLC)
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.3 Eli Lilly And Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Acquisition and Mergers:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 Takeda Pharmaceutical Company Limited
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expense
7.6 Sanofi S.A.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 BioMarin Pharmaceutical Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Approvals and Trials:
7.10. Sigilon Therapeutics, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses

For more information about this report visit https://www.researchandmarkets.com/r/1lxuzy